These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12678235)

  • 41. A Vero cell method for potency testing of diphtheria vaccines.
    Winsnes R; Sesardic D; Daas A; Rigsby P
    Dev Biol (Basel); 2002; 111():141-8. PubMed ID: 12678233
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development and validation of a serological potency test for the release of Leptospira vaccines--requirements in the European Union.
    Balks E; Gyra H; Kobe B; Cussler K; Werner E
    Biologicals; 2013 Sep; 41(5):325-9. PubMed ID: 23911253
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Progress in the replacement of animal experiments in the quality control of clostridial vaccines].
    Cussler K; Borrmann E; Werner E
    Dtsch Tierarztl Wochenschr; 2002 Apr; 109(4):172-7. PubMed ID: 11998369
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Aerosol immunization of ducks with Spirovak erysipelas vaccine "Dessau"].
    Müller H; Reetz G
    Arch Exp Veterinarmed; 1980; 34(1):55-7. PubMed ID: 7416894
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Replacement, reduction or refinement of animal use in the quality control of veterinary vaccines: development, validation and implementation.
    van der Kamp MD
    Dev Biol Stand; 1996; 86():73-6. PubMed ID: 8785994
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protective immunity of SpaA-antigen producing Lactococcus lactis against Erysipelothrix rhusiopathiae infection.
    Cheun HI; Kawamoto K; Hiramatsu M; Tamaoki H; Shirahata T; Igimi S; Makino SI
    J Appl Microbiol; 2004; 96(6):1347-53. PubMed ID: 15139928
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Towards eliminating the use of animals for regulatory required vaccine quality control.
    Hendriksen CF
    ALTEX; 2006; 23(3):187-90. PubMed ID: 17086348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alternatives to animal experimentation. The sophisticated process of validation.
    Schwanig M
    ALTEX; 1998; 15(5):6-9. PubMed ID: 11178525
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of an in vitro potency test for tetanus vaccines: an immunoassay based on Hc fragment determination.
    Prieur S; Broc S; Gal M; Poirier B; Fuchs F
    Dev Biol (Basel); 2002; 111():37-46. PubMed ID: 12678223
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adoption of three Rs alternatives for regulatory testing of vaccines in the developing world: possibilities and barriers.
    Di Fabio JL; Jaramillo MT; Arciniega JL
    Dev Biol (Basel); 2002; 111():195-8. PubMed ID: 12678241
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative efficacy of an indigenous 'inactivated vaccine' using highly pathogenic field strain of Mycobacterium avium subspecies paratuberculosis 'Bison type' with a commercial vaccine for the control of Capri-paratuberculosis in India.
    Singh SV; Singh PK; Singh AV; Sohal JS; Gupta VK; Vihan VS
    Vaccine; 2007 Oct; 25(41):7102-10. PubMed ID: 17804124
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Product-specific validation of a serological potency test for release of Leptospira vaccines in the European Union.
    Stirling C; Novokova V
    Biologicals; 2013 Sep; 41(5):330-1. PubMed ID: 23849308
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Protective antigens of the swine erysipelas bacterium (Erysipelothrix rhusiopathiae. 1. Specific demonstration of the protective antigen].
    Rothe F
    Arch Exp Veterinarmed; 1982; 36(2):243-53. PubMed ID: 6808965
    [No Abstract]   [Full Text] [Related]  

  • 55. Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement.
    Hendriksen CF
    Expert Rev Vaccines; 2009 Mar; 8(3):313-22. PubMed ID: 19249973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Studies of the occurrence of erysipelas bacteria in healthy swine in the Hungarian People's Republic with reference to possible use of erysipelas live vaccines].
    Kucsera G
    Arch Exp Veterinarmed; 1980; 34(1):63-5. PubMed ID: 7416896
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of antibiotics on the immune system of animals. II. Mouse experiments with an inactivated adsorbed vaccine against swine erysipelas.
    Tu TD
    Acta Vet Acad Sci Hung; 1981; 28(3):309-16. PubMed ID: 7258019
    [No Abstract]   [Full Text] [Related]  

  • 58. Problems of erysipelas. 3. Streptococcal vaccine treatment of relapsing erysipelas.
    Korossy S; Rajka O; Böszörményi J; Gózony M
    Acta Med Acad Sci Hung; 1968; 25(1):51-61. PubMed ID: 5678738
    [No Abstract]   [Full Text] [Related]  

  • 59. Development of improved attenuated and nucleic acid vaccines for heartwater.
    Collins NE; Pretorius A; van Kleef M; Brayton KA; Allsopp MT; Zweygarth E; Allsopp BA
    Dev Biol (Basel); 2003; 114():121-36. PubMed ID: 14677683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of a monoclonal antibody for in vitro potency testing of erysipelas bacterins.
    Henderson LM; Jenkins PS; Scheevel KF; Walden DM
    Dev Biol Stand; 1996; 86():334. PubMed ID: 8785974
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.